Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

22.10.13	Thomson Reuters ONE/Novartis a réalisé, au -3- (Dow Jones)
05.10.13	Press Release: Novartis announces positive -2- (Dow Jones)
05.10.13	Press Release: Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU (Dow Jones)
04.10.13	Press Release: New data show Novartis' Gilenya(R) -2- (Dow Jones)
04.10.13	Press Release: New data show Novartis' Gilenya(R) reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients (Dow Jones)
03.10.13	Press Release: Real-world evidence showed -2- (Dow Jones)
03.10.13	Press Release: Real-world evidence showed superiority of Novartis' Gilenya(R) to reduce MS relapse rates compared to interferons or glatiramer acetate (Dow Jones)
03.10.13	Press Release: Secukinumab (AIN457) showed -2- (Dow Jones)
03.10.13	Press Release: Secukinumab (AIN457) showed superiority over Enbrel(R) in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV (Dow Jones)
27.09.13	Press Release: New data for Novartis drug -2- (Dow Jones)
27.09.13	Press Release: New data for Novartis drug Lucentis(R) reinforces transformational efficacy and well-established safety profile across four indications (Dow Jones)
25.09.13	Press Release: Data at ECTRIMS to confirm -2- (Dow Jones)
25.09.13	Press Release: Data at ECTRIMS to confirm Novartis' Gilenya(R) long-term efficacy on reducing brain volume loss and real-world relapse rates in MS (Dow Jones)
23.09.13	Thomson Reuters ONE/Malaria No More und Novartis starten "Power of One", eine weltweite digitale Spendenkampagne, die zur Ausmerzung von Malaria bedingten... (Dow Jones)
23.09.13	Thomson Reuters ONE/Malaria No More et Novartis lancent Power of One, une campagne numérique mondiale de collecte de fonds visant à contribuer à l'élimina... (Dow Jones)
23.09.13	Press Release: Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths (Dow Jones)
23.09.13	Press Release: Novartis first-in-class once-daily -3- (Dow Jones)
23.09.13	Press Release: Novartis first-in-class once-daily -2- (Dow Jones)
23.09.13	Press Release: Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Eu... (Dow Jones)
19.09.13	Press Release: Novartis marks World CML Day with -3- (Dow Jones)
19.09.13	Press Release: Novartis marks World CML Day with -2- (Dow Jones)
19.09.13	Press Release: Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free (Dow Jones)
08.09.13	PRESS RELEASE: Novartis data presented at ERS -3- (Dow Jones)
08.09.13	PRESS RELEASE: Novartis data presented at ERS -2- (Dow Jones)
08.09.13	PRESS RELEASE: Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro(R) Breezhaler(R) (QVA149) (Dow Jones)
06.09.13	PRESS RELEASE: Novartis announces an exclusive global licensing and research collaboration with Regenerex, leveraging a novel cell platform to broaden presen... (Dow Jones)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts -4- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts -3- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts -2- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013 (Dow Jones)
04.09.13	PRESS RELEASE: Novartis marks 30 year anniversary -2- (Dow Jones)
04.09.13	PRESS RELEASE: Novartis marks 30 year anniversary in transplantation and reinforces continued commitment to organ recipients at ESOT congress (Dow Jones)
03.09.13	PRESS RELEASE: Novartis receives EU approval for -2- (Dow Jones)
03.09.13	PRESS RELEASE: Novartis receives EU approval for Ilaris(R) in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis (Dow Jones)
02.09.13	PRESS RELEASE: Novartis' serelaxin (RLX030) -2- (Dow Jones)
02.09.13	PRESS RELEASE: Novartis' serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2] (Dow Jones)
26.08.13	Thomson Reuters ONE/Novartis veranstaltet jährlichen Wettbewerb für unternehmerisches Denken im Gesundheitswesen, der Einblicke in die Branche und künftig... (Dow Jones)
26.08.13	PRESS RELEASE: Novartis holds annual healthcare entrepreneur competition to generate insight into healthcare and innovation of tomorrow (Dow Jones)
26.08.13	Thomson Reuters ONE/Novartis organise son concours annuel des entrepreneurs du secteur de la santé pour un voyage au coeur de la santé et de l'innovation ... (Dow Jones)
20.08.13	PRESS RELEASE: Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM) (Dow Jones)
15.08.13	PRESS RELEASE: Novartis vaccine Bexsero(R) -2- (Dow Jones)
15.08.13	PRESS RELEASE: Novartis vaccine Bexsero(R) approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis (Dow Jones)
08.08.13	PRESS RELEASE: Novartis first company accredited with global "CEO Cancer Gold Standard" for outstanding efforts in cancer prevention and treatment (Dow Jones)
07.08.13	PRESS RELEASE: Novartis study of Afinitor(R) in -2- (Dow Jones)
07.08.13	PRESS RELEASE: Novartis study of Afinitor(R) in advanced liver cancer does not meet primary endpoint of overall survival (Dow Jones)
02.08.13	PRESS RELEASE: Novartis: FDA expands age -2- (Dow Jones)
02.08.13	PRESS RELEASE: Novartis: FDA expands age indication for Menveo(R), first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1] (Dow Jones)
26.07.13	PRESS RELEASE: Novartis receives positive CHMP -2- (Dow Jones)
26.07.13	PRESS RELEASE: Novartis receives positive CHMP opinion for Ilaris(R) in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis (Dow Jones)
26.07.13	PRESS RELEASE: Novartis first in class once-daily -3- (Dow Jones)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt